- Home
- Publications
- Publication Search
- Publication Details
Title
Romidepsin
Authors
Keywords
-
Journal
DRUGS
Volume 71, Issue 11, Pages 1469-1480
Publisher
Springer Nature
Online
2011-08-05
DOI
10.2165/11207170-000000000-00000
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma
- (2011) R. L. Piekarz et al. BLOOD
- Deciphering the molecular and biologic processes that mediate histone deacetylase inhibitor-induced thrombocytopenia
- (2011) M. J. Bishton et al. BLOOD
- Chemoproteomics profiling of HDAC inhibitors reveals selective targeting of HDAC complexes
- (2011) Marcus Bantscheff et al. NATURE BIOTECHNOLOGY
- The histone deacetylase inhibitors vorinostat and romidepsin downmodulate IL-10 expression in cutaneous T-cell lymphoma cells
- (2010) CE Tiffon et al. BRITISH JOURNAL OF PHARMACOLOGY
- Peripheral T-cell lymphoma: autologous hematopoietic cell transplantation as first-line therapy
- (2010) Ginna G Laport CURRENT OPINION IN ONCOLOGY
- Current and Emerging Treatment Strategies for Cutaneous T-cell Lymphoma
- (2010) Frederick Lansigan et al. DRUGS
- Histone deacetylase inhibitors: potential targets responsible for their anti-cancer effect
- (2010) Michael Dickinson et al. INVESTIGATIONAL NEW DRUGS
- Final Results From a Multicenter, International, Pivotal Study of Romidepsin in Refractory Cutaneous T-Cell Lymphoma
- (2010) Sean J. Whittaker et al. JOURNAL OF CLINICAL ONCOLOGY
- Chemical phylogenetics of histone deacetylases
- (2010) James E Bradner et al. Nature Chemical Biology
- Acquired vorinostat resistance shows partial cross-resistance to ‘second-generation’ HDAC inhibitors and correlates with loss of histone acetylation and apoptosis but not with altered HDAC and HAT activities
- (2009) Konstantin J. Dedes et al. ANTI-CANCER DRUGS
- Laboratory correlates for a phase II trial of romidepsin in cutaneous and peripheral T-cell lymphoma
- (2009) Susan E. Bates et al. BRITISH JOURNAL OF HAEMATOLOGY
- Epigenetic Modifiers: Basic Understanding and Clinical Development
- (2009) R. L. Piekarz et al. CLINICAL CANCER RESEARCH
- Cytotoxicity Mediated by Histone Deacetylase Inhibitors in Cancer Cells: Mechanisms and Potential Clinical Implications
- (2009) D. S. Schrump CLINICAL CANCER RESEARCH
- Rational Combinations Using HDAC Inhibitors
- (2009) M. Bots et al. CLINICAL CANCER RESEARCH
- Histone Deacetylase Inhibitors
- (2009) Xujun Ma et al. DRUGS
- Reactivation of DNA viruses in association with histone deacetylase inhibitor therapy: a case series report
- (2009) D. Ritchie et al. HAEMATOLOGICA
- Histone Deacetylase Inhibitors in Cancer Therapy
- (2009) Andrew A. Lane et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Multi-Institutional Trial of the Histone Deacetylase Inhibitor Romidepsin As Monotherapy for Patients With Cutaneous T-Cell Lymphoma
- (2009) Richard L. Piekarz et al. JOURNAL OF CLINICAL ONCOLOGY
- Management of T-cell and natural-killer-cell neoplasms in Asia: consensus statement from the Asian Oncology Summit 2009
- (2009) Yok-Lam Kwong et al. LANCET ONCOLOGY
- Update on the World Health Organization classification of peripheral T-cell lymphomas
- (2009) Hilary M. O’Leary et al. Current Hematologic Malignancy Reports
- International Peripheral T-Cell and Natural Killer/T-Cell Lymphoma Study: Pathology Findings and Clinical Outcomes
- (2008) JOURNAL OF CLINICAL ONCOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started